TARA Protara Therapeutics, Inc.
Financings ·
Protara's January 2025 presentation says cash runway reaches into 2027 when it counts $102.7 million of gross proceeds from a recent offering. Its balance sheet figure is $81.5 million at September 30, 2024, and its bladder cancer efficacy data come from a small single-arm trial.
We have not published a story on Protara Therapeutics yet. When there is news, it will appear here.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $42.6 million | $31.7 million |
| Net income (loss) | -$57.4 million | -$44.6 million |
| Cash from operations | -$56.4 million | -$35.8 million |
| Cash and equivalents | $49.7 million | $162.8 million |
| Short-term investments | $105.9 million | $7.5 million |
Opinion Mixed view
Protara has $142.5 million and a bladder cancer trial with small, open-label, uncontrolled interim data whose response rate fell by half between six and 12 months. Spending is rising, and the company says it will need new capital.
Our latest story on this, dated Jan 13, 2025: "Protara Therapeutics puts cash runway into 2027, counting $102.7 million offering". The story links the filing or release it is based on. Read the story.
Protara Therapeutics, Inc. trades under the ticker TARA on NASDAQ.
Protara Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1KPA.
The SEC Central Index Key (CIK) for Protara Therapeutics, Inc. is 1359931. Its filings are on SEC EDGAR.
59,095,488 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Protara Therapeutics, Inc. under United States.
Our directory classifies Protara Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Protara Therapeutics, Inc. is US74365U1079.
aibio.space lists Protara Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Protara Therapeutics, Inc. reported a net loss of $57.4 million for the fiscal year ended Dec 31, 2025, and used $56.4 million of cash in operations, per its annual report to the SEC.
$42.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
$142.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Protara Therapeutics, dated Jan 13, 2025: "Protara Therapeutics puts cash runway into 2027, counting $102.7 million offering". Protara's January 2025 presentation says cash runway reaches into 2027 when it counts $102.7 million of gross proceeds from a recent offering. Its balance sheet figure is $81.5 million at September 30, 2024, and its bladder cancer efficacy data come from a small single-arm trial. Source.
From our story of Jan 13, 2025: Protara's January 2025 presentation says cash runway reaches into 2027 when it counts $102.7 million of gross proceeds from a recent offering. Source.
We do not publish live share prices. In its annual report, Protara Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $112.3 million as of Jun 30, 2025.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio